A new evidence points to promising results that can potentially provide a new treatment avenue for men with prostate cancer aiming for surgery, the use of apalutamide as a neoadjuvant therapy. The study showed that this treatment might facilitate better recovery of sexual function after the operation, This way addressing one of the major quality-of-life issues among patients with prostate cancer.
Globally, prostate cancer is one of the top cancers diagnosed in men. Thanks to technology, the survival rate has improved dramatically over the last decades. Yet, several of the patients end up experiencing after-effects, In particular those who have undergone radical prostatectomy (removal of the prostate gland) to get rid of cancer.
A major side effect of prostate cancer surgery is the risk of sexual dysfunction. That explains why despite advancements that help surgeons avoid nerve damage, erectile dysfunction still occurs in most men at least temporarily after surgery. There are several factors like age, general health state, cancer stage, and level of surgery that influence how fast and well the patient will recover. It is no wonder that researchers are still on the lookout for ways to enhance functional outcomes without allowing any compromise in cancer control.
This is where apalutamide comes into the picture. It is a very potent androgen receptor antagonist which has been proven in clinical trials to be effective in treating different stages of prostate cancer. The drug works by blocking the male hormones that might lead to prostate cancer cell growth. But, researchers are not only interested in cancer-killing effects- they want to know whether preoperative treatment with apalutamide can be more beneficial in overall cancer therapy.
The rationale behind neoadjuvant therapy is using the drugs earlier, the treatment could be more effective. In theory, this could impair cancer cell growth even more and at the same time promote tissue healing and help tackle the surgery side-effects better. The scientists tested the patients to check the effectiveness of apalutamide given as a neoadjuvant treatment.
The findings were very much welcomed by the cancer doctor fraternity. They noted that the sexual function seems to get restored faster in the patients treated with apalutamide even after the surgery compared to the expected outcomes from the records. The knock-on effect is that it seems promising in enhancing the quality of life post-intervention as well.
Alongside killing cancer cells, experts argue that restoring sexual potency is one of the pillars of a good cancer survivors’ care plan. After all, a successful treatment means the provider must not stop at the eradication of the disease, but also address long-lasting impacts on patients. And for a lot of men, sexual well-being is a big contributor to their sense of self mood social life, and satisfaction with life in general.
Using apalutamide could help more than simply turning back the clock on one’s physical ability. The fear of unpleasant side effects largely affects whether and which treatment the patient decides for. It is true that better outcome-induced therapies would be less stressful for the patient and they may also be a source of hope.
Studies show that hormones and cancer cells interact with one another leading to changes in the environment inside the body. Apalutamide modulates hormone pathways and as a result can alter tumor biology. Thereby, a healthier nerve function and stronger tissue can be preserved resulting in faster healing. The research wanting to shed more light on this is underway.
